This is a newsletter designed for enthusiasts of science and medicine.
Please consider subscribing if one of our content categories piques your interest (see below).
Thank you for your time, and happy reading.
Please feel free to contact us at [email protected]
Weekly Readout
A digest of new clinical data from the past week.
These include…
…landmark FDA approvals:
1st FDA-approval for genetic hearing loss
1st FDA-approval for PROTACs
…potentially first-in-disease medicines, based on positive clinical data:
1st successful Phase 3 trial for an in vivo CRISPR gene-editing therapy (link)
1st successful Phase 3 trial for oral non-hormonal treatment for hair loss in nearly 30 year
…potentially best-in-disease or best-in-class medicines, based on positive clinical data:
For plaque psoriasis
Frontiers in Medicine
Exploring the frontiers of our understanding and treatments for disease.
These include…
Obesity (Part 1, Part 2)
Acquisitions
Exploring the innovation behind acquired companies.
These include…
…scientist-founded companies, which start with the foundational work of a researcher and organically grow into a biotech company:
Chiesi to Acquire KalVista, an oral HAE play
Eli Lilly to Acquire Ajax, a differentiated JAK play
…entrepreneur-led asset aggregators, which are focused on building a pipeline of licensed drugs that are ‘potentially better versions’ of other drugs that have already achieved clinical/commercial success:
UCB to Acquire Candid, scooping a reverse merger for a TCE pipeline